Steven Gillis - Sep 13, 2022 Form 4 Insider Report for Codiak BioSciences, Inc. (CDAKQ)

Role: Director
Signature: /s/ Mark McDonnell by Power of Attorney for Steven Gillis
Stock symbol: CDAKQ
Transactions as of: Sep 13, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/15/2022, 06:54 PM
Previous filing: Jun 21, 2022
Next filing: Jan 30, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CDAKQ	Common Stock	Purchase		+5M	+199.69%		7.5M	Sep 13, 2022	See footnotes	F1, F2, F3
holding	CDAKQ	Common Stock						10.3K	Sep 13, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDAKQ	Warrant (Right to Buy)	Purchase		+5M			5M	Sep 13, 2022	Common Stock	5M	$1.88	See footnotes	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share.
F2	Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.
F3	The Reporting Person is a managing director at ARCH Partners VIII and owns an interest in ARCH Partners VIII but does not have voting or investment control over the shares and warrants held by ARCH Fund VIII. The Reporting Person disclaims beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.